On September 11, 2020 Phost’in Therapeutics (Montpellier,France), a research-driven biopharmaceutical company developing N-glycosylation inhibitors as a First-in-Class immunotherapy for cancer treatment, reported that it will receive a €2.5 million funding from Bpifrance in addition to its recent Series-A round (Press release, Phost’in, SEP 11, 2020, View Source [SID1234565009]). This non-dilutive funding includes €2 million from Bpifrance’s Deeptech program, initiated by the French government, to boost highly innovative and breakthrough projects emerging from fundamental research and to strengthen the country’s competitive advantage in the field. Proceeds will be used to advance the regulatoryand early-clinical development ofPhost’in’s main program PhOx430 for the next two years. To date, Phost’in Therapeutics has raised a total of €16 million.The company has previously announced in April 2020a €10.3 million Series A round from an international syndicate of Life Science and Innovation Investors led by Remiges Ventures, providing the company resources to bring PhOx430 into clinical trials by 12 months with a focus on aggressive solid tumorssuch as Glioblastomas and Triple Negative Breast Cancers. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for immune response suppression. Karine Chorro, co-founder and CEO of Phost’in Therapeutics, said "Joining the deep tech community represents the recognition of our N-glycosylation inhibitors as a breakthrough disruptive innovation. Plus, it will enable us to largely accelerate the development of our main program PhOx430 towards clinical trials, for the full benefit of patients still suffering from very limited therapeutic options. We are very excitedto move forward in this next step with the support ofBpifrance." "At Bpifra nce,we work hard to identify and support disruptive technologies correlated with strong entrepreneurial spirit, in any world-changing fields that will be transformative for generations to come. We are enthusiastic about the cutting-edge science behindthe program,coming from years of academic researches in several top-level French institutes, and strongly believe in Phost’in’s capacity to deliver its first-in-class candidate to patients suffering from rare and aggressive cancers" noted Nadine Faedo, Regional Director at Bpifrance. "Therefore, we foresee Bpifrance as a long-term partner of choice for Phost’in to install its leadership in the field of Glyco-Immuno-Oncology".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020 (Press release, Pacira Pharmaceuticals, SEP 11, 2020, View Source [SID1234565027]). Live audio of the virtual event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 1:20 p.m. EDT (Press release, Heron Therapeutics, SEP 11, 2020, View Source [SID1234565043]). The conference is being held in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On September 11, 2020 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 1:20 p.m. EDT (Press release, Heron Therapeutics, SEP 11, 2020, View Source [SID1234565010]). The conference is being held in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On September 11, 2020 Mundipharma reported that Great Place to Work – the global authority on workplace culture – has named it as one of Europe’s Best Workplaces (Press release, Mundipharma, SEP 11, 2020, View Source [SID1234565028]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mundipharma is ranked 12th out of 25 organisations in the Multi-National Company category. Great Place to Work have recognised a total of 125 organisations across four categories in its newly published Europe’s Best Workplaces 2020 list.

Great Place to Work analyzed survey results representing 3,000 organisations and 1.5 million employees across Europe. The survey measured trust and engagement of employees using a series of statements designed to evaluate experience of organizational culture.

This European achievement was made possible after Great Place to Work presented a number of National ‘Best Workplaces awards to Mundipharma companies earlier this year, including Spain, Netherlands, Portugal and Napp.

These European awards follow similar success from across the global Mundipharma network including across the Asia Region. So far this year, Hong Kong, China, Myanmar and Vietnam have all received ‘Best Company’ recognitions from prestigious national awarding bodies.

Speaking about the results, Mundipharma’s Global CEO, Marc Princen, said "Awards like these are testament to our focus on building an inclusive learning culture at Mundipharma where every employee feels appreciated. We believe that people are our most valued asset and if individuals feel accountable, and have the power to make a difference, they can not only deliver for the business but more importantly for the patients we serve."

The EU list publication has come during the COVID-19 pandemic, which has placed unprecedented pressures upon businesses and employees globally. Organizations on the list are being celebrated for leading the way amid the pandemic, demonstrating care for their employees, their customers and their communities during difficult and exceptional times.